SpringWorks Therapeutics Reports First Quarter 2024
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the…
SpringWorks Therapeutics Reports First Quarter 2024
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the…
SpringWorks Therapeutics Announces Abstracts Accepted for
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted…
SpringWorks Therapeutics Announces European Medicines
STAMFORD, Conn., Feb. 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq:…
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
Shares of Immunome, Inc. IMNM were up 36.9% on Feb 6 after…
